IFN-α was approved by the United States Food and Drug Administration to be used as the standard of care in advanced melanoma; however, its’ further clinical application is hampered by the high cost of drug administration, limited efficacy, and adverse constitutional events. Here, IFNA1 is linked to melanoma.